


Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at tctmd.com


Clinical Evidence Review of LAAO Synthesizes What’s Known and What’s Still Unclear. bit.ly/4t9lL2r

Tune in! @MarcBonaca and @CMichaelGibson discuss the functional effects and patient progress with once-weekly semaglutide for type 2 diabetes and PAD. Listen to the full podcast here: bit.ly/4fctirC

MAR001, an investigational therapy targeting ANGPTL4, lowered triglyceride levels in the phase IIa TYDAL-TIMI 78 study. Whether that translates into lower CV risk remains unknown. bit.ly/4BSYVA8

High-dose heparin doesn't bolster clinical benefit over a lower dose during elective PCI, the HD-PCI trial shows. bit.ly/4iLNCB0 #CAD #CardiovascularArteryDisease


Many Strategies on the Table for Treatment of Calcified Coronary Lesions: TCT Session bit.ly/4zkpnA9

For patients with atrioventricular block, left bundle branch pacing produced better outcomes than right ventricular pacing in the randomized OptimPacing trial. bit.ly/4iL81q7

Can older adults without known CVD safely stop statins used for primary prevention? STREAM suggests discontinuation may be reasonable in select patients—but it’s not without risk. bit.ly/3Wx0AeE

SUPERIOR: Sacubitril/Valsartan May Lessen AF Recurrence After Ablation bit.ly/4kUMduA

In a post-hoc OCEANIC-STROKE analysis, asundexian was associated with better outcomes after noncardioembolic stroke or high-risk TIA regardless of baseline vascular risk according to Framingham Risk Score. bit.ly/3X6Yx0Z

Tight blood pressure control after an ischemic stroke or TIA lowers the risk of major adverse cardiovascular events over the next 4 years, the OPTIMAL-STROKE trial suggests. bit.ly/4zdiFff

Guiding DAPT De-escalation With Platelet Function Testing Doesn’t Improve Outcomes: EPIC17-VERONICA bit.ly/4kRsHiB

Can targeting inflammation still reduce cardiovascular events? ZEUS found no benefit with ziltivekimab, but experts say the inflammatory hypothesis may not be finished. bit.ly/4sXU2lt


Lp(a)HORIZON did not show the hoped-for cardiovascular benefits of reducing lipoprotein(a). Still, experts caution that one neutral trial does not end the pursuit of effective Lp(a)-lowering therapies. bit.ly/4iQa0t9